Collaboration aimed at discovery and development of small molecule inhibitors through to Phase I proof of mechanism in metabolic disorders therapeutic area.
Jubilant Biosys and Sanofi Deutschland GmbH enter into a Strategic Alliance
Collaboration aimed at discovery and development of small molecule inhibitors through to Phase I proof of mechanism in metabolic disorders therapeutic area.
We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness of campaigns and analyse traffic. If you continue to use this site we will assume your acceptance.